Article
Prognostic role and treatment tips of FHL1 expression in cytogenetically intermediate- and poor-risk acute myeloid leukemia
2020-03-13
Abstract excerpt
<h4>Background: </h4> Acute myeloid leukemia (AML) is a heterogeneous disorder of hematopoietic system, 35 to 40% of younger patients (<60 years) are recurrent, refractory or drug-resistant, which are canonically called as cytogenetically intermediate- and poor-risk AML (IP-AML). Identifying novel biomarkers is an urgent clinical need and research hotspot for treatment optimization. <h4>Methods:</h4> Bioinformatic...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d7993eaf-d724-5d28-a2e4-c8da3f5fd345
- DOI
- 10.21203/rs.3.rs-17167/v1
